Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Cannabidiol
Therapeutic Area : Dermatology
Study Phase : Approved FDF
Recipient : Avicanna
Deal Size : Undisclosed
Deal Type : Partnership
Details : CBD has been shown to promote skin health by inducing antioxidant, anti-inflammatory, and anti-apoptotic responses that could be beneficial for a variety of dermatological conditions such as eczema or atopic dermatitis.
Product Name : Pura H&W
Product Type : Controlled Substance
Upfront Cash : Undisclosed
April 05, 2022
Lead Product(s) : Cannabidiol
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Recipient : Avicanna
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Cannabinoid,MicroSilver BG
Therapeutic Area : Dermatology
Study Phase : Phase I
Recipient : Avicanna
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Bio-Gate is developing active cosmetic and dermatology products in collaboration with Avicanna that combine MicroSilver BG™ and CBD (hemp derived) to deliver synergistic anti-inflammatory and antimicrobial effects.
Product Name : re+PLAY
Product Type : Controlled Substance
Upfront Cash : Inapplicable
June 29, 2021
Lead Product(s) : Cannabinoid,MicroSilver BG
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Recipient : Avicanna
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
